DK0741784T3 - Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler - Google Patents

Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler

Info

Publication number
DK0741784T3
DK0741784T3 DK95907739T DK95907739T DK0741784T3 DK 0741784 T3 DK0741784 T3 DK 0741784T3 DK 95907739 T DK95907739 T DK 95907739T DK 95907739 T DK95907739 T DK 95907739T DK 0741784 T3 DK0741784 T3 DK 0741784T3
Authority
DK
Denmark
Prior art keywords
ligand
cells
activated
receptor
ligands
Prior art date
Application number
DK95907739T
Other languages
English (en)
Inventor
Wayne Godfrey
Edgar George Engleman
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22723580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0741784(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK0741784T3 publication Critical patent/DK0741784T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
DK95907739T 1994-02-10 1995-02-06 Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler DK0741784T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/195,967 US6242566B1 (en) 1994-02-10 1994-02-10 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
PCT/GB1995/000238 WO1995021915A1 (en) 1994-02-10 1995-02-06 Ligand (act-4-l) to a receptor on the surface of activated cd4+ t-cells

Publications (1)

Publication Number Publication Date
DK0741784T3 true DK0741784T3 (da) 2009-06-22

Family

ID=22723580

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95907739T DK0741784T3 (da) 1994-02-10 1995-02-06 Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler

Country Status (12)

Country Link
US (10) US6242566B1 (da)
EP (1) EP0741784B1 (da)
JP (4) JP3703834B2 (da)
AT (1) ATE425252T1 (da)
AU (1) AU1583695A (da)
CA (1) CA2183066A1 (da)
DE (1) DE69535929D1 (da)
DK (1) DK0741784T3 (da)
ES (1) ES2323392T3 (da)
HK (1) HK1001462A1 (da)
PT (1) PT741784E (da)
WO (1) WO1995021915A1 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821332A (en) * 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) * 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
JP3914342B2 (ja) * 1997-09-25 2007-05-16 武田薬品工業株式会社 ｇｐ３４結合阻害物を有効成分として含有する医薬組成物
DK1060247T3 (da) * 1998-02-24 2009-01-26 Sisters Of Providence In Orego Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US7622557B2 (en) * 1998-05-28 2009-11-24 St. Jude Children's Research Hospital Antibodies having binding specificity for the extracellular domain of a breast cancer resistance protein (BCRP)
CA2399388A1 (en) 2000-02-11 2001-08-16 Michael J. Lenardo Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
GB0123276D0 (en) * 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
PL376536A1 (pl) 2002-08-28 2006-01-09 Immunex Corporation Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
CA2503748A1 (en) * 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
EP1578782A4 (en) * 2002-12-30 2007-09-12 Amgen Inc COSTIMULATING FACTORIAL THERAPY
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
ES2605380T3 (es) * 2005-05-06 2017-03-14 Providence Health & Services - Oregon Proteina de fusión OX40-inmunoglobulina trimérica y métodos de uso
AU2011265482B2 (en) * 2005-05-06 2013-08-29 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
AR057253A1 (es) 2005-12-16 2007-11-21 Genentech Inc Anticuerpos anti-ox40l y metodos que los utilizan
CN101426268B (zh) * 2007-11-02 2010-08-25 大唐移动通信设备有限公司 导频资源分配方法、系统和设备
PE20120211A1 (es) * 2009-02-17 2012-03-24 Ucb Pharma Sa Anticuerpos que tienen especificidad por ox40 humana
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
CA2863818A1 (en) 2012-02-06 2013-08-15 Brendan CURTI Cancer treatment and monitoring methods using ox40 agonists
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
US10696946B2 (en) * 2013-02-22 2020-06-30 The Board Of Trustees Of The University Of Illinois T-REG cell expansion
PL2964638T3 (pl) 2013-03-06 2018-01-31 Astrazeneca Ab Inhibitory chinazolinowe aktywujących zmutowanych postaci receptora epidermalnego czynnika wzrostu
EP3052106A4 (en) * 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10307472B2 (en) 2014-03-12 2019-06-04 Curevac Ag Combination of vaccination and OX40 agonists
CA2948054A1 (en) 2014-04-03 2015-10-08 Augusta University Research Institute, Inc. Methods for enhancing the efficacy of a tumor-directed immune response
JP6666267B2 (ja) 2014-05-29 2020-03-13 メディミューン，エルエルシー Ｏｘ４０ｌ融合タンパク質およびその使用
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
KR20230128139A (ko) 2014-10-24 2023-09-01 아스트라제네카 아베 조합물
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
CN114504652A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
CA2984794A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
MY188049A (en) 2015-05-29 2021-11-12 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
CN108348780A (zh) 2015-09-10 2018-07-31 贝克顿·迪金森公司 用作用于环磷酰胺和异环磷酰胺的免疫分析的免疫原和分析缀合物的环磷酰胺类似物
AU2016328357B2 (en) * 2015-09-22 2023-03-02 Ventana Medical Systems, Inc. Anti-OX40 antibodies and diagnostic uses thereof
CA3007233A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
CA3025812A1 (en) 2016-08-19 2018-02-22 Curevac Ag Rna for cancer therapy
KR20190093816A (ko) 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
US11043823B2 (en) * 2017-04-06 2021-06-22 Tesla, Inc. System and method for facilitating conditioning and testing of rechargeable battery cells
JP7206258B2 (ja) 2017-09-21 2023-01-17 ベクトン・ディキンソン・アンド・カンパニー 危険汚染物質の収集キット及び迅速試験
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
JP7479385B2 (ja) 2019-01-28 2024-05-08 ベクトン・ディキンソン・アンド・カンパニー 一体化されたスワブ及び検査デバイスを有する有害汚染物質採取デバイス
US20220354880A1 (en) 2019-09-30 2022-11-10 Astrazeneca Ab Combination treatment for cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51146432A (en) * 1975-06-12 1976-12-16 Microbial Chem Res Found Process for preparation of benzanilide derivatives having therapeutic action to immunological disease
DK0432249T3 (da) 1989-06-02 1997-02-17 Univ Johns Hopkins Med Monoklonale antistoffer over for beta-kæden i leukocytadhæsionsreceptoren, fremgangsmåder til fremstilling af disse antistoffer og anvendelse heraf
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
CA2100084A1 (en) 1991-01-11 1992-07-12 James R. Rusche Method of preventing inflammatory damage
US5376367A (en) * 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5329028A (en) * 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5821332A (en) * 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US5759546A (en) 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
JP3914342B2 (ja) 1997-09-25 2007-05-16 武田薬品工業株式会社 ｇｐ３４結合阻害物を有効成分として含有する医薬組成物

Also Published As

Publication number Publication date
US20030149247A1 (en) 2003-08-07
JP2005245448A (ja) 2005-09-15
US20020077460A1 (en) 2002-06-20
US6528055B2 (en) 2003-03-04
US20010044523A1 (en) 2001-11-22
US6242566B1 (en) 2001-06-05
WO1995021915A1 (en) 1995-08-17
JPH09509826A (ja) 1997-10-07
EP0741784B1 (en) 2009-03-11
US7125670B2 (en) 2006-10-24
JP3703834B2 (ja) 2005-10-05
US20070092511A1 (en) 2007-04-26
US20040006207A1 (en) 2004-01-08
US6156878A (en) 2000-12-05
JP4745872B2 (ja) 2011-08-10
US20060217531A1 (en) 2006-09-28
US7098184B2 (en) 2006-08-29
US20100240873A1 (en) 2010-09-23
HK1001462A1 (en) 1998-06-19
ES2323392T3 (es) 2009-07-14
US6528623B2 (en) 2003-03-04
EP0741784A1 (en) 1996-11-13
AU1583695A (en) 1995-08-29
JP2006254914A (ja) 2006-09-28
CA2183066A1 (en) 1995-08-17
US20090069535A1 (en) 2009-03-12
PT741784E (pt) 2009-06-18
ATE425252T1 (de) 2009-03-15
JP4109263B2 (ja) 2008-07-02
DE69535929D1 (de) 2009-04-23
JP2010046060A (ja) 2010-03-04

Similar Documents

Publication Publication Date Title
DK0741784T3 (da) Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler
ATE454449T1 (de) Menschlicher rezeptor h4-1bb
HUP9802483A2 (hu) Szolubilis limfotoxin-béta-receptorok, limfotoxin-receptorra és -ligandumra specifikus antitestek alkalmazása terápiás ágensként immunológiai betegségek kezelésére
EE03285B1 (et) Immuunsust stimuleerivad monoklonaalsed antikehad
DE68925226T2 (de) Monoklonale Antikörper
DE69738692D1 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
ATE331531T1 (de) Lösliche lymphotoxin-beta rezeptoren, anti- lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
DE69116629D1 (de) Vorrichtung zur Vergrösserung des Signal-/Rauschverhältnisses von magnetostatischen Wellen und FM- oder PM-Empfangsgerät, das diese Vorrichtung benutzt
DK0639275T3 (da) Hidtil ukendte GABAa-receptorundertyper og fremgangsmåder til screening af lægemiddelforbindelser under anvendelse af imidazoquinoxaliner og pyrrolopyimidiner til binding til GABAa-receptorundertyper
ES2121358T3 (es) Anticuerpos monoclonales humanizados contra interleuquina-4 humana.
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DK0568554T3 (da) Fremgangsmåde til påvisning af anti-RNA-antistoffer
DK0841939T3 (da) Terapeutiske midler og autoimmune sygdomme
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
TR199800604A2 (xx) Anti-fas antikorlar�.
Górski et al. Depressed immune surveillance against cancer: role of deficient T cell: extracellular matrix interactions
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
ATE108664T1 (de) Verfahren zur verhütung von gvhd.
ATE173503T1 (de) Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma
FR2599513B1 (fr) Anticorps monoclonaux inhibant la liaison de ige soluble aux lymphocytes humains, hybridomes monoclonaux produisant de tels anticorps, leur utilisation
IL122426A (en) Method of identifying persons susceptible to neuropsychiatric disorders
HAMMARSTRÖM et al. Characterization of a Mitogenic Antilymphocyte Monoclonal Antibody of the IgM Isotype Obtained by Immunization with Leukoagglutinin‐Reactive Human T‐Lymphocyte Surface Components a